CLAIMS

1. A composition comprising at least two compounds selected from ifenprodil, acamprosate, almitrine, azelastine, baclofen, carbetapentane, cinacalcet, dexbrompheniramine, diethylcarbamazine, D-mannose, fenspiride, levosimendan, mexiletine, nicergoline, tolfenamic acid, tolperisone, torasemide and triamterene, for use in the treatment of diabetes or a related disorder in a mammalian in need thereof.

2. The composition for use of claim 1, wherein said composition comprises ifenprodil and at least one compound selected from acamprosate, almitrine, azelastine, baclofen, carbetapentane, cinacalcet, dexbrompheniramine, diethylcarbamazine, D-mannose, fenspiride, levosimendan, mexiletine, nicergoline, tolfenamic acid, tolperisone, torasemide and triamterene.

3. The composition for use of claim 1, wherein said composition comprises acamprosate and at least one compound selected from almitrine, azelastine, baclofen, carbetapentane, cinacalcet, dexbrompheniramine, diethylcarbamazine, D-mannose, fenspiride, ifenprodil, levosimendan, mexiletine, nicergoline, tolfenamic acid, tolperisone, torasemide and triamterene.

4. A composition comprising i) at least one compound selected from acamprosate, almitrine, azelastine, baclofen, carbetapentane, cinacalcet, dexbrompheniramine, diethylcarbamazine, D-mannose, fenspiride, ifenprodil, levosimendan, mexiletine, nicergoline, tolfenamic acid, tolperisone, torasemide, and triamterene in combination with ii) at least one distinct compound selected from acamprosate, almitrine, amlexanox, azelastine, baclofen, carbetapentane, cinacalcet, dexbromopheniramine, diethylcarbamazine, D-mannose, fenspiride, fexofenadine, ifenprodil, mexiletine, nicergoline, tolperisone, torasemide, triamterene, tolfenamic acid, piribedil, levosimendan, cimetidine, diprophylline, idebenone and rilmenidine, for use in the treatment of diabetes or a related disorder in a mammalian in need thereof.

5. The composition for use of anyone of claims 1 to 4, wherein said composition comprises at least one of the following combinations of compounds:
   - ifenprodil and acamprosate,
   - ifenprodil and baclofen,

- D-mannose and baclofen,
- baclofen and acamprosate,
- mexiletine and cinacalcet,
- mexiletine and torasemide,
- sulfisoxazole and torasemide,
- azelastine and nicergoline,
- idebenone and nicergoline,
- carbetapentane and nicergoline,
- almitrine and nicergoline,
- cimetidine and nicergoline,
- diethylcarbamazine and nicergoline,
- ifenprodil and nicergoline,
- azelastine and idebenone,
- acamprosate and nicergoline,
- azelastine and carbetapentane,
- azelastine and almitrine,
- idebenone and carbetapentane,
- idebenone and almitrine,
- triamterene and nicergoline,
- D-Mannose and nicergoline,
- idebenone and diethylcarbamazine,
- ifenprodil and fenspiride,
- ifenprodil and torasemide,
- ifenprodil and triamterene,
- ifenprodil and tolfenamic acid,
- fenspiride and torasemide,
- fenspiride and triamterene,
- fenspiride and tolfenamic acid,
- torasemide and triamterene,
- torasemide and tolfenamic acid, or
- triamterene and tolfenamic acid.

6. A composition comprising at least one compound selected from acamprosate, almitrine, azelastine, baclofen, carbetapentane, cinacalcet, dexbrompheniramine,

diethylcarbamazine, D-mannose, fenspiride, ifenprodil, levosimendan, mexiletine, nicergoline, tolfenamic acid, tolperisone, torasemide, and triamterene, in combination with at least one further anti-diabetic agent, for use in the treatment of diabetes or a related disorder in a mammalian in need thereof.

7. The composition for use of claim 6, wherein the at least one further anti-diabetic agent is selected from acarbose, acetohexamide, alogliptin, berberine, bezafibrate, bromocriptine, buformin, carbutamide, chlorpropamide, chromium picolinate, ciprofibrate, clofibrate, colesevelam, dexfenfluramine, dutogliptin, exenatide, fenofibrate, gemfibrozil, gemigliptin, glibenclamide, glibornuride, glicetanile, gliclazide, glimepiride, glipizide, gliquidone, glisentide, glyclopyramide, imidapril, insulin, inulin, lipoic acid, linagliptin, liraglutide, mecobalamin, metformin, miglitol, mitiglinide, nateglinide, orlistat, phenformin, pioglitazone, pramlintide, repaglinide, rosiglitazone, saxagliptin, sitagliptin, tolazamide, tolbutamide, vildagliptin or voglibose.

8. The composition for use of claim 7 wherein the at least one further anti-diabetic agent is metformin.

9. The composition for use of claim 8 wherein said composition comprises metformin in combination with at least one of the following combinations of compounds :

- D-mannose and baclofen,
- ifenprodil and acamprosate,
- ifenprodil and baclofen,
- baclofen and acamprosate,
- mexiletine and cinacalcet,
- mexiletine and torasemide,
- sulfisoxazole and torasemide,
- azelastine and nicergoline,
- idebenone and nicergoline,
- carbetapentane and nicergoline,
- almitrine and nicergoline,
- cimetidine and nicergoline,
- diethylcarbamazine and nicergoline,
- ifenprodil and nicergoline,

- azelastine and idebenone,
- acamprosate and nicergoline,
- azelastine and carbetapentane,
- azelastine and almitrine,
- idebenone and carbetapentane,
- idebenone and almitrine,
- triamterene and nicergoline,
- D-mannose and nicergoline,
- idebenone and diethylcarbamazine,
- ifenprodil and fenspiride,
- ifenprodil and torasemide,
- ifenprodil and triamterene,
- ifenprodil and tolfenamic acid,
- fenspiride and torasemide,
- fenspiride and triamterene,
- fenspiride and tolfenamic acid,
- torasemide and triamterene,
- torasemide and tolfenamic acid, or
- triamterene and tolfenamic acid.

10. The composition for use of any one of the preceding claims, wherein the compound(s) control(s) blood glucose level in a diabetic patient.

11. A composition of any one of claims 1 to 10, for use for increasing or stimulating glucose uptake in adipocytes and/or muscular cells in a mammalian subject, particularly in a mammalian subject having diabetes or a related disorder.

12. A composition of any one of claims 1 to 10, for use for decreasing apoptosis of pancreatic beta cells in a mammalian subject, particularly in a mammalian subject having diabetes or a related disorder.

13. The composition for use of any one of the preceding claims, wherein the diabetes is type 2 diabetes.

14. A composition of any one of claims 1 to 10, for use for decreasing insulin resistance in a mammalian subject having type-2 diabetes.

15. The composition for use of any one of the preceding claims, which further comprises a pharmaceutically acceptable carrier or excipient.

16. The composition for use of any one of the preceding claims, wherein the compounds in said composition are formulated or administered together, separately or sequentially.

17. The composition for use of any one of the preceding claims, wherein said composition is administered repeatedly to the subject.

CLAIMS

1. Use of a composition comprising ifenprodil or fenspiride, or salt(s), prodrug(s), derivative(s) or sustained release formulation(s) thereof, in the preparation of a medicament for use in the treatment of diabetes or of a related disorder selected from impaired glucose tolerance, impaired fasting glucose, insulin resistance, metabolic syndrome, postprandial hyperglycemia and overweight/obesity in a mammalian subject in need thereof.

2. The use of claim 1, wherein said composition further comprises at least one distinct compound selected from acamprosate, almitrine, amlexanox, azelastine, baclofen, carbetapentane, cinacalcet, dexbromopheniramine, diethylcarbamazine, D-mannose, fenspiride, fexofenadine, ifenprodil, mexiletine, nicergoline, tolperisone, torasemide, triamterene, tolfenamic acid, piribedil, levosimendan, cimetidine, diprophylline, idebenone and rilmenidine, or salt(s), prodrug(s), derivative(s) or sustained release formulation(s) thereof.

3. The use according to claim 2, wherein the at least one distinct compound is selected from acamprosate, almitrine, azelastine, baclofen, carbetapentane, cinacalcet, dexbrompheniramine, diethylcarbamazine, D-mannose, fenspiride, ifenprodil, levosimendan, mexiletine, nicergoline, tolfenamic acid, tolperisone, torasemide and triamterene, or salt(s), prodrug(s), derivative(s) or sustained release formulation(s) thereof.

4. The use according to anyone of claim 1 or 2, wherein said composition comprises at least one of the following combinations of compounds:
   - ifenprodil and acamprosate,
   - ifenprodil and baclofen,
   - ifenprodil and nicergoline,
   - ifenprodil and fenspiride,
   - ifenprodil and torasemide,
   - ifenprodil and triamterene,
   - ifenprodil and tolfenamic acid,
   - fenspiride and torasemide,
   - fenspiride and triamterene,
   - fenspiride and tolfenamic acid,

   or salt(s), prodrug(s), derivative(s) or sustained release formulation(s) thereof.

5. The use according to anyone of the preceding claims, further comprising at least one anti-diabetic agent.

6. The use according to claim 5, wherein the at least one further anti-diabetic agent is selected from acarbose, acetohexamide, alogliptin, berberine, bezafibrate, bromocriptine, buformin, carbutamide, chlorpropamide, chromium picolinate, ciprofibrate, clofibrate, colesevelam, dexfenfluramine, dutogliptin, exenatide, fenofibrate, gemfibrozil, gemigliptin, glibenclamide, glibornuride, glicetanile, gliclazide, glimepiride, glipizide, gliquidone, glisentide, glyclopyramide, imidapril, insulin, inulin, lipoic acid, linagliptin, liraglutide, mecobalamin, metformin, miglitol, mitiglinide, nateglinide, orlistat, phenformin, pioglitazone, pramlintide, repaglinide, rosiglitazone, saxagliptin, sitagliptin, tolazamide, tolbutamide, vildagliptin or voglibose, or salt(s), prodrug(s), derivative(s) or sustained release formulation(s) thereof.

7. The use of claim 5, wherein the at least one further anti-diabetic agent is metformin or a salt, prodrug, derivative or sustained release formulation thereof.

8. The use of claim 7, wherein said composition comprises at least one of the following combinations of compounds :
   - ifenprodil and metformin,
   - fenspiride and metformin,
   - ifenprodil and acamprosate and metformin,
   - ifenprodil and baclofen and metformin,
   - ifenprodil and nicergoline and metformin,
   - ifenprodil and fenspiride and metformin,
   - ifenprodil and torasemide and metformin,
   - ifenprodil and triamterene and metformin,
   - ifenprodil and tolfenamic acid and metformin,
   - fenspiride and torasemide and metformin,
   - fenspiride and triamterene and metformin,
   - fenspiride and tolfenamic acid and metformin,

   or salt(s), prodrug(s), derivative(s) or sustained release formulation(s) thereof.

9. A use according to any one of the preceding claims, wherein said medicament is for controlling blood glucose level in mammalian subject in need thereof.

10. The use of claim 9, wherein the mammalian subject is suffering from diabetes or from a related disorder selected from impaired glucose tolerance, impaired fasting glucose, insulin resistance, metabolic syndrome, postprandial hyperglycemia and overweight/obesity.

11. The use according to any one of claims 1 to 10, wherein the compound(s) of said medicament increase(s) or stimulate(s) glucose uptake in adipocytes and/or muscular cells in said mammalian subject.

12. The use according to any one of claims 1 to 10, wherein the compound(s) of said medicament decrease(s) apoptosis of pancreatic beta cells in said mammalian subject.

13. The use according to any one of claims 1 to 8, wherein the medicament is for decreasing insulin resistance in a mammalian subject in a mammalian subject in need thereof.

14. The use according to claims 1, 9 and 13, wherein the subject is suffering from type 2 diabetes.

15. The use according to any one of the preceding claims, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient.

16. The use according to any one of the preceding claims, wherein the compounds in said composition are formulated or administered together, separately or sequentially.

17. The use according to any one of the preceding claims, wherein said medicament is administered repeatedly to the subject.